comprehensive -WSS

comprehensive

author：focus 2025-10-02 00:20:06 Page View：561

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Health AI: on the border between health care and tech
Next article： Cancer drug shortages should be causing more outrage

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Maui wildfire now ranks as the fifth

4:12Theshellsofburnedcarsandbuildingsareleftafterwildfiresdrivenbyhighwindsburnedacrossmostofthetown

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

ChrisWinterstandsinherhomeinJuneau,Alaska,onMonday,Aug.7,2023,afteraweekendglaciallakeoutburstfloodr